JP2011504490A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011504490A5 JP2011504490A5 JP2010534598A JP2010534598A JP2011504490A5 JP 2011504490 A5 JP2011504490 A5 JP 2011504490A5 JP 2010534598 A JP2010534598 A JP 2010534598A JP 2010534598 A JP2010534598 A JP 2010534598A JP 2011504490 A5 JP2011504490 A5 JP 2011504490A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- nicotine
- disease
- pharmaceutically acceptable
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 229960002715 nicotine Drugs 0.000 claims 10
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 10
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 claims 9
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 claims 9
- YNZFUWZUGRBMHL-UHFFFAOYSA-N 2-[4-[3-(11-benzo[b][1]benzazepinyl)propyl]-1-piperazinyl]ethanol Chemical compound C1CN(CCO)CCN1CCCN1C2=CC=CC=C2C=CC2=CC=CC=C21 YNZFUWZUGRBMHL-UHFFFAOYSA-N 0.000 claims 8
- 238000000586 desensitisation Methods 0.000 claims 8
- 229960005290 opipramol Drugs 0.000 claims 8
- 239000003112 inhibitor Substances 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 6
- 210000003169 central nervous system Anatomy 0.000 claims 6
- 239000000181 nicotinic agonist Substances 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 4
- 208000025569 Tobacco Use disease Diseases 0.000 claims 4
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 150000002148 esters Chemical class 0.000 claims 4
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 4
- 210000001428 peripheral nervous system Anatomy 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 208000030507 AIDS Diseases 0.000 claims 3
- 206010057852 Nicotine dependence Diseases 0.000 claims 3
- -1 bretyrol Chemical compound 0.000 claims 3
- 238000013270 controlled release Methods 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 230000005586 smoking cessation Effects 0.000 claims 3
- CXFZFEJJLNLOTA-UHFFFAOYSA-N 4-[(3-chlorophenyl)carbamoyloxy]but-2-ynyl-trimethylazanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC#CCOC(=O)NC1=CC=CC(Cl)=C1 CXFZFEJJLNLOTA-UHFFFAOYSA-N 0.000 claims 2
- 208000007848 Alcoholism Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000009829 Lewy Body Disease Diseases 0.000 claims 2
- 201000002832 Lewy body dementia Diseases 0.000 claims 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical group CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims 2
- JUOSGGQXEBBCJB-UHFFFAOYSA-N Metanicotine Natural products CNCCC=CC1=CC=CN=C1 JUOSGGQXEBBCJB-UHFFFAOYSA-N 0.000 claims 2
- FXFANIORDKRCCA-UHFFFAOYSA-N Norcotinine Chemical compound N1C(=O)CCC1C1=CC=CN=C1 FXFANIORDKRCCA-UHFFFAOYSA-N 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 2
- 201000004810 Vascular dementia Diseases 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 229960004606 clomipramine Drugs 0.000 claims 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims 2
- 230000001149 cognitive effect Effects 0.000 claims 2
- 206010013663 drug dependence Diseases 0.000 claims 2
- 229960004194 lidocaine Drugs 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- 208000018726 traumatic encephalopathy Diseases 0.000 claims 2
- MXYUKLILVYORSK-UHFFFAOYSA-N (+/-)-allo-lobeline Natural products C1CCC(CC(=O)C=2C=CC=CC=2)N(C)C1CC(O)C1=CC=CC=C1 MXYUKLILVYORSK-UHFFFAOYSA-N 0.000 claims 1
- UIKROCXWUNQSPJ-VIFPVBQESA-N (-)-cotinine Chemical group C1CC(=O)N(C)[C@@H]1C1=CC=CN=C1 UIKROCXWUNQSPJ-VIFPVBQESA-N 0.000 claims 1
- MXYUKLILVYORSK-HBMCJLEFSA-N (-)-lobeline Chemical compound C1([C@@H](O)C[C@H]2N([C@H](CCC2)CC(=O)C=2C=CC=CC=2)C)=CC=CC=C1 MXYUKLILVYORSK-HBMCJLEFSA-N 0.000 claims 1
- ZSTLCHCDLIUXJE-ZGBAEQJLSA-N (2S,5S)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate dihydrochloride Chemical compound O.Cl.Cl.C1S[C@@H](C)O[C@@]21C(CC1)CCN1C2.C1S[C@@H](C)O[C@@]21C(CC1)CCN1C2 ZSTLCHCDLIUXJE-ZGBAEQJLSA-N 0.000 claims 1
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims 1
- VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 claims 1
- BUJAGSGYPOAWEI-SECBINFHSA-N (2r)-2-amino-n-(2,6-dimethylphenyl)propanamide Chemical compound C[C@@H](N)C(=O)NC1=C(C)C=CC=C1C BUJAGSGYPOAWEI-SECBINFHSA-N 0.000 claims 1
- PHOZOHFUXHPOCK-QMMMGPOBSA-N (2s)-2-ethyl-8-methyl-1-thia-4,8-diazaspiro[4.5]decan-3-one Chemical compound N1C(=O)[C@H](CC)SC11CCN(C)CC1 PHOZOHFUXHPOCK-QMMMGPOBSA-N 0.000 claims 1
- WUTYZMFRCNBCHQ-WPRPVWTQSA-N (2s,5s)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] Chemical compound C1S[C@@H](C)O[C@@]21C(CC1)CCN1C2 WUTYZMFRCNBCHQ-WPRPVWTQSA-N 0.000 claims 1
- YHXKVHQFWVYXIC-JTQLQIEISA-N (S)-nicotine 1-N-oxide Chemical compound CN1CCC[C@H]1C1=CC=C[N+]([O-])=C1 YHXKVHQFWVYXIC-JTQLQIEISA-N 0.000 claims 1
- MYKUKUCHPMASKF-VIFPVBQESA-N (S)-nornicotine Chemical compound C1CCN[C@@H]1C1=CC=CN=C1 MYKUKUCHPMASKF-VIFPVBQESA-N 0.000 claims 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims 1
- DUHUCHOQIDJXAT-OLVMNOGESA-N 3-hydroxy-(3-α,5-α)-Pregnane-11,20-dione Chemical compound C([C@@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1=O DUHUCHOQIDJXAT-OLVMNOGESA-N 0.000 claims 1
- XOKCJXZZNAUIQN-IENPIDJESA-N 3-hydroxycotinine Chemical compound C1C(O)C(=O)N(C)[C@@H]1C1=CC=CN=C1 XOKCJXZZNAUIQN-IENPIDJESA-N 0.000 claims 1
- BBNHNZGTKSWIHD-SNVBAGLBSA-N 5'-Hydroxycotinine Chemical compound CN1C(=O)CC[C@@]1(O)C1=CC=CN=C1 BBNHNZGTKSWIHD-SNVBAGLBSA-N 0.000 claims 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims 1
- GUDVQJXODNJRIJ-CALCHBBNSA-N 9-[3-[(3S,5R)-3,5-dimethyl-1-piperazinyl]propyl]carbazole Chemical compound C1[C@@H](C)N[C@@H](C)CN1CCCN1C2=CC=CC=C2C2=CC=CC=C21 GUDVQJXODNJRIJ-CALCHBBNSA-N 0.000 claims 1
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 claims 1
- UIKROCXWUNQSPJ-UHFFFAOYSA-N Cotinine Natural products C1CC(=O)N(C)C1C1=CC=CN=C1 UIKROCXWUNQSPJ-UHFFFAOYSA-N 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- RPYWXZCFYPVCNQ-RVDMUPIBSA-N DMXB-A Chemical compound COC1=CC(OC)=CC=C1\C=C/1C(C=2C=NC=CC=2)=NCCC\1 RPYWXZCFYPVCNQ-RVDMUPIBSA-N 0.000 claims 1
- NLPRAJRHRHZCQQ-UHFFFAOYSA-N Epibatidine Natural products C1=NC(Cl)=CC=C1C1C(N2)CCC2C1 NLPRAJRHRHZCQQ-UHFFFAOYSA-N 0.000 claims 1
- DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 claims 1
- 241000208125 Nicotiana Species 0.000 claims 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims 1
- MYKUKUCHPMASKF-UHFFFAOYSA-N Nornicotine Natural products C1CCNC1C1=CC=CN=C1 MYKUKUCHPMASKF-UHFFFAOYSA-N 0.000 claims 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims 1
- 208000024571 Pick disease Diseases 0.000 claims 1
- ILLGYRJAYAAAEW-QMMMGPOBSA-N abt-418 Chemical compound CN1CCC[C@H]1C1=CC(C)=NO1 ILLGYRJAYAAAEW-QMMMGPOBSA-N 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 229960003305 alfaxalone Drugs 0.000 claims 1
- 229960005260 amiodarone Drugs 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims 1
- 229960000623 carbamazepine Drugs 0.000 claims 1
- 229960001314 cevimeline Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940112822 chewing gum Drugs 0.000 claims 1
- 235000015218 chewing gum Nutrition 0.000 claims 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims 1
- 229960004126 codeine Drugs 0.000 claims 1
- 229950006073 cotinine Drugs 0.000 claims 1
- CIPULDKLIIVIER-VIFPVBQESA-N cotinine N-oxide Chemical compound C1CC(=O)N(C)[C@@H]1C1=CC=CN(=O)=C1 CIPULDKLIIVIER-VIFPVBQESA-N 0.000 claims 1
- 229950000405 decamethonium Drugs 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 claims 1
- 229960001066 disopyramide Drugs 0.000 claims 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- NLPRAJRHRHZCQQ-IVZWLZJFSA-N epibatidine Chemical compound C1=NC(Cl)=CC=C1[C@@H]1[C@H](N2)CC[C@H]2C1 NLPRAJRHRHZCQQ-IVZWLZJFSA-N 0.000 claims 1
- GEEFPQBPVBFCSD-XHNCKOQMSA-N epiboxidine Chemical compound O1N=C(C)C=C1[C@@H]1[C@H](N2)CC[C@H]2C1 GEEFPQBPVBFCSD-XHNCKOQMSA-N 0.000 claims 1
- ZFOJLLQHJIXKHO-UHFFFAOYSA-N epiquinamide Natural products C1CCCC2C(NC(=O)C)CCCN21 ZFOJLLQHJIXKHO-UHFFFAOYSA-N 0.000 claims 1
- 229960000449 flecainide Drugs 0.000 claims 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims 1
- 229960001848 lamotrigine Drugs 0.000 claims 1
- 229960002339 lobeline Drugs 0.000 claims 1
- 229930013610 lobeline Natural products 0.000 claims 1
- SAPNXPWPAUFAJU-UHFFFAOYSA-N lofepramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1CCCN(C)CC(=O)C1=CC=C(Cl)C=C1 SAPNXPWPAUFAJU-UHFFFAOYSA-N 0.000 claims 1
- 229960002813 lofepramine Drugs 0.000 claims 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 claims 1
- 229960002409 mepivacaine Drugs 0.000 claims 1
- 229960003404 mexiletine Drugs 0.000 claims 1
- NCGLTZSBTFVVAW-KNXRZYMVSA-N minaxolone Chemical compound C1[C@@H](N(C)C)[C@@H]2[C@@]3(C)C[C@H](OCC)[C@@H](O)C[C@@H]3CC[C@H]2[C@@H]2CC[C@H](C(C)=O)[C@]21C NCGLTZSBTFVVAW-KNXRZYMVSA-N 0.000 claims 1
- 229960004798 minaxolone Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- ZFOJLLQHJIXKHO-GHMZBOCLSA-N n-[(1r,9ar)-2,3,4,6,7,8,9,9a-octahydro-1h-quinolizin-1-yl]acetamide Chemical compound C1CCC[C@@H]2[C@H](NC(=O)C)CCCN21 ZFOJLLQHJIXKHO-GHMZBOCLSA-N 0.000 claims 1
- 239000007922 nasal spray Substances 0.000 claims 1
- 229940097496 nasal spray Drugs 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 claims 1
- 229960005301 pentazocine Drugs 0.000 claims 1
- 208000027232 peripheral nervous system disease Diseases 0.000 claims 1
- 229960002036 phenytoin Drugs 0.000 claims 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 claims 1
- 229960000244 procainamide Drugs 0.000 claims 1
- 229960003712 propranolol Drugs 0.000 claims 1
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 claims 1
- 229960002601 protriptyline Drugs 0.000 claims 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims 1
- 229960004431 quetiapine Drugs 0.000 claims 1
- 229960001404 quinidine Drugs 0.000 claims 1
- 229950004933 rimcazole Drugs 0.000 claims 1
- JUOSGGQXEBBCJB-GORDUTHDSA-N rivanicline Chemical compound CNCC\C=C\C1=CC=CN=C1 JUOSGGQXEBBCJB-GORDUTHDSA-N 0.000 claims 1
- 229960002370 sotalol Drugs 0.000 claims 1
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- MKTAGSRKQIGEBH-SSDOTTSWSA-N tebanicline Chemical compound C1=NC(Cl)=CC=C1OC[C@@H]1NCC1 MKTAGSRKQIGEBH-SSDOTTSWSA-N 0.000 claims 1
- 239000010409 thin film Substances 0.000 claims 1
- 229960004605 timolol Drugs 0.000 claims 1
- 229960002872 tocainide Drugs 0.000 claims 1
- HLXQFVXURMXRPU-UHFFFAOYSA-L trimethyl-[10-(trimethylazaniumyl)decyl]azanium;dibromide Chemical compound [Br-].[Br-].C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C HLXQFVXURMXRPU-UHFFFAOYSA-L 0.000 claims 1
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 claims 1
- 229960004751 varenicline Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99016107P | 2007-11-26 | 2007-11-26 | |
| US60/990,161 | 2007-11-26 | ||
| PCT/IL2008/001546 WO2009069126A1 (en) | 2007-11-26 | 2008-11-26 | Compositions comprising nicotinic agonists and methods of using same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011504490A JP2011504490A (ja) | 2011-02-10 |
| JP2011504490A5 true JP2011504490A5 (enExample) | 2012-01-19 |
| JP5456687B2 JP5456687B2 (ja) | 2014-04-02 |
Family
ID=40380297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010534598A Expired - Fee Related JP5456687B2 (ja) | 2007-11-26 | 2008-11-26 | ニコチン作動薬を含む組成物及びそれを用いる方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US8273731B2 (enExample) |
| EP (1) | EP2224917B1 (enExample) |
| JP (1) | JP5456687B2 (enExample) |
| KR (1) | KR101613742B1 (enExample) |
| CN (1) | CN101925352B (enExample) |
| AR (1) | AR069752A1 (enExample) |
| AU (1) | AU2008331102B2 (enExample) |
| BR (1) | BRPI0819911A2 (enExample) |
| CA (1) | CA2744736C (enExample) |
| CL (1) | CL2008003507A1 (enExample) |
| CY (1) | CY1119768T1 (enExample) |
| DK (1) | DK2224917T3 (enExample) |
| ES (1) | ES2642873T3 (enExample) |
| HR (1) | HRP20171476T1 (enExample) |
| HU (1) | HUE035105T2 (enExample) |
| LT (1) | LT2224917T (enExample) |
| MX (1) | MX2010005804A (enExample) |
| PL (1) | PL2224917T3 (enExample) |
| PT (1) | PT2224917T (enExample) |
| SI (1) | SI2224917T1 (enExample) |
| WO (1) | WO2009069126A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2008003507A1 (es) | 2007-11-26 | 2009-11-27 | Neuroderm Ltd | Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico. |
| WO2010014760A1 (en) | 2008-08-01 | 2010-02-04 | Zoran Corporation | Video encoder with an integrated temporal filter for denoising |
| US9801865B2 (en) * | 2008-09-24 | 2017-10-31 | The United States Of America As Represented By The Department Of Veteran Affairs | Materials and methods for diagnosis, prevention and/or treatment of stress disorders and conditions associated with abeta peptide aggregation |
| US8529914B2 (en) * | 2010-06-28 | 2013-09-10 | Richard C. Fuisz | Bioactive dose having containing a material for modulating pH of a bodily fluid to help or hinder absorption of a bioactive |
| SMT201700010T1 (it) | 2011-04-29 | 2017-03-08 | Moberg Pharma Ab | Composizioni farmaceutiche comprendenti un anestetico locale come bupivacaina per somministrazione locale alla bocca o alla gola |
| EP2872899B1 (en) * | 2012-07-13 | 2018-07-11 | Pain Therapeutics, Inc. | Alzheimer's disease assay in a living patient |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| EP4299128A3 (en) | 2014-03-13 | 2024-04-17 | Neuroderm Ltd. | Dopa decarboxylase inhibitor compositions |
| US20170216273A1 (en) * | 2014-05-29 | 2017-08-03 | Jory F. Goodman | Nicotine Derivatives and Methods of Use |
| US20180140610A1 (en) * | 2014-09-18 | 2018-05-24 | Neuroderm, Ltd. | Opipramol patch |
| EP4413974A3 (en) | 2014-10-20 | 2024-10-09 | Oyster Point Pharma, Inc. | Methods of treating ocular conditions |
| KR102574658B1 (ko) | 2014-12-05 | 2023-09-05 | 쥴 랩스, 인크. | 교정된 투여량 제어 |
| PT3439661T (pt) | 2016-04-07 | 2021-09-30 | Oyster Point Pharma Inc | Métodos de tratamento de condições oculares |
| US10292977B2 (en) * | 2016-04-11 | 2019-05-21 | Neurocea, LLC | Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases |
| CA3014725C (en) * | 2016-04-12 | 2020-09-22 | Arturo Solis Herrera | Compositions and methods for treating nasal and paranasal mucosa diseases with nicotinic acetylcholine receptor agonists |
| WO2018097629A1 (ko) * | 2016-11-24 | 2018-05-31 | 에스케이케미칼 주식회사 | 바레니클린 서방성 제제 및 이의 제조 방법 |
| US11260050B2 (en) | 2017-02-16 | 2022-03-01 | United States Government As Represented By The Department Of Veterans Affairs | Combination of cotinine plus antioxidant for treatment-resistant depression and correction of astrocytes functional deficit induced by depression and other neuropathological |
| US20200000822A1 (en) * | 2017-02-23 | 2020-01-02 | Board Of Regents, The University Of Texas System | Methods of treatment for cancer, sterol homeostasis, and neurological diseases |
| US10961296B2 (en) | 2017-11-10 | 2021-03-30 | Howard Hughes Medical Institute | Modified ligand-gated ion channels and methods of use |
| LU101519B1 (en) * | 2019-12-02 | 2021-06-07 | Herrera Arturo Solis | (S)-3-[1-MethyIpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical in form of a solid substance and a tablet |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US12161612B2 (en) | 2023-04-14 | 2024-12-10 | Neuroderm, Ltd. | Methods and compositions for reducing symptoms of Parkinson's disease |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5069094A (en) * | 1987-09-08 | 1991-12-03 | Birkestrand Orville J | Tube end finishing machine |
| US5656286A (en) * | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| US5668117A (en) | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
| US5336675A (en) * | 1991-05-14 | 1994-08-09 | Ernir Snorrason | Method of treating mania in humans |
| WO1993023045A1 (en) * | 1992-05-18 | 1993-11-25 | Pharmaco Behavioral Associates, Inc. | Use of cotinine to alleviate tobacco withdrawal syndrome |
| JPH09262287A (ja) * | 1996-03-28 | 1997-10-07 | Terumo Corp | 薬液注入装置 |
| WO1998009523A1 (en) * | 1996-09-05 | 1998-03-12 | Massachusetts Institute Of Technology | Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
| DE10018834A1 (de) * | 2000-04-15 | 2001-10-25 | Lohmann Therapie Syst Lts | Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung |
| CA2418135C (en) * | 2000-08-03 | 2011-09-20 | Antares Pharma Ipl Ag | Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels |
| US20070225379A1 (en) * | 2001-08-03 | 2007-09-27 | Carrara Dario Norberto R | Transdermal delivery of systemically active central nervous system drugs |
| US6479076B2 (en) * | 2001-01-12 | 2002-11-12 | Izhak Blank | Nicotine delivery compositions |
| DE10134038A1 (de) | 2001-07-12 | 2003-02-06 | Hf Arzneimittelforsch Gmbh | Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit |
| US20030119879A1 (en) | 2001-10-15 | 2003-06-26 | Thomas Landh | Nicotine and chocolate compositions |
| US6852741B2 (en) * | 2001-12-31 | 2005-02-08 | University Of Florida | Compositions and methods for treatment of neurological disorders |
| US7045534B2 (en) * | 2002-02-12 | 2006-05-16 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of reducing angiogenesis |
| PT1587506E (pt) * | 2002-12-18 | 2008-10-30 | Algorx | Administração de capasaicinóides |
| ITMI20030828A1 (it) | 2003-04-18 | 2004-10-19 | Farchemia Srl | Procedimento per la preparazione dell'opipramolo. |
| PT1670433E (pt) * | 2003-10-10 | 2012-02-08 | Ferring Bv | Fórmula farmacológica transdérmica para a minimização de resíduos na pele |
| US20050191349A1 (en) * | 2003-12-31 | 2005-09-01 | Garth Boehm | Galantamine formulations |
| US20050234024A1 (en) * | 2004-04-14 | 2005-10-20 | Clarke David E | Materials and methods for the treatment of ulcerative colitis |
| US20050277626A1 (en) | 2004-05-27 | 2005-12-15 | Neurocure Ltd. | Methods and compositions for treatment of nicotine dependence and dementias |
| US20060142349A1 (en) * | 2004-12-23 | 2006-06-29 | Pfizer Inc | Methods of modulating the activities of alpha-7 nicotinic acetylcholine receptor |
| US20080014252A1 (en) * | 2006-07-14 | 2008-01-17 | Delprete Keith | Topical compositions with long lasting effect |
| WO2008011484A2 (en) | 2006-07-18 | 2008-01-24 | Bethesda Pharmacology Associates, Llc | Nicotinic desensitizers and methods of selecting, testing, and using them |
| EP2255848A3 (en) * | 2006-09-04 | 2011-04-06 | NeuroSearch AS | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer |
| CL2008003507A1 (es) | 2007-11-26 | 2009-11-27 | Neuroderm Ltd | Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico. |
-
2008
- 2008-11-25 CL CL2008003507A patent/CL2008003507A1/es unknown
- 2008-11-26 WO PCT/IL2008/001546 patent/WO2009069126A1/en not_active Ceased
- 2008-11-26 HU HUE08855517A patent/HUE035105T2/en unknown
- 2008-11-26 BR BRPI0819911A patent/BRPI0819911A2/pt not_active IP Right Cessation
- 2008-11-26 ES ES08855517.2T patent/ES2642873T3/es active Active
- 2008-11-26 KR KR1020107014088A patent/KR101613742B1/ko not_active Expired - Fee Related
- 2008-11-26 CA CA2744736A patent/CA2744736C/en not_active Expired - Fee Related
- 2008-11-26 AU AU2008331102A patent/AU2008331102B2/en not_active Ceased
- 2008-11-26 JP JP2010534598A patent/JP5456687B2/ja not_active Expired - Fee Related
- 2008-11-26 MX MX2010005804A patent/MX2010005804A/es active IP Right Grant
- 2008-11-26 PT PT88555172T patent/PT2224917T/pt unknown
- 2008-11-26 EP EP08855517.2A patent/EP2224917B1/en not_active Not-in-force
- 2008-11-26 US US12/323,779 patent/US8273731B2/en not_active Expired - Fee Related
- 2008-11-26 LT LTEP08855517.2T patent/LT2224917T/lt unknown
- 2008-11-26 HR HRP20171476TT patent/HRP20171476T1/hr unknown
- 2008-11-26 CN CN200880126096.9A patent/CN101925352B/zh not_active Expired - Fee Related
- 2008-11-26 DK DK08855517.2T patent/DK2224917T3/en active
- 2008-11-26 SI SI200831872T patent/SI2224917T1/sl unknown
- 2008-11-26 AR ARP080105141A patent/AR069752A1/es not_active Application Discontinuation
- 2008-11-26 PL PL08855517T patent/PL2224917T3/pl unknown
-
2012
- 2012-08-24 US US13/593,911 patent/US8921356B2/en not_active Expired - Fee Related
-
2014
- 2014-11-26 US US14/554,660 patent/US20150306109A1/en not_active Abandoned
-
2016
- 2016-09-08 US US15/259,752 patent/US20170128432A1/en not_active Abandoned
-
2017
- 2017-10-04 CY CY20171101027T patent/CY1119768T1/el unknown
- 2017-11-30 US US15/827,293 patent/US20180303818A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011504490A5 (enExample) | ||
| HRP20171476T1 (hr) | Pripravak koji sadrži nikotin i opipramol te upotreba istog | |
| JP3861250B2 (ja) | ５−ｈｔ２拮抗剤による強迫性障害処置剤 | |
| PH12014502531B1 (en) | Benzamine derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 | |
| JP2012521994A5 (enExample) | ||
| RU2014121065A (ru) | Бензойная кислота, производные бензойной кислоты и конъюгаты гетероарилкарбоновой кислоты с гидроморфоном, пролекарства, способы получения и их применение | |
| JP6992109B2 (ja) | ｍＧｌｕＲ２陰性アロステリック調節剤としてのクロマン、イソクロマン及びジヒドロイソベンゾフラン誘導体、組成物、及びそれらの使用 | |
| JP2013518914A5 (enExample) | ||
| JP2003509369A5 (enExample) | ||
| TW200831140A (en) | Controlled-release formulation of piperazine-piperidine antagonists and agonists of the 5-HT1A receptor having enhanced intestinal dissolution | |
| CN102164927A (zh) | 用作多巴胺d3受体调节剂的异唑并[4,5]吡啶-3-基-哌嗪衍生物 | |
| JP2006522128A5 (enExample) | ||
| JP2016514688A5 (enExample) | ||
| RS20050892A (sr) | Derivati imidazola kao antagonisti glutamatnih receptora | |
| CN103442711A (zh) | 精神分裂症中的认知功能障碍的治疗方法 | |
| US20250034106A1 (en) | 3-cycloamino-indole compounds as serotonergic agents useful for the treatment of disorders related thereto | |
| JP2018523644A (ja) | アルコール乱用の治療におけるγ−ヒドロキシ酪酸の選択されたアミドおよびその使用 | |
| JP5528434B2 (ja) | ニューロンｎＡＣｈＲの無痛性脱感作剤およびその使用方法 | |
| KR20000064711A (ko) | 우울성장애및양극성장애치료에서(+)-알파-(2,3-디메톡시페닐)-1-[2-(4-플루오로페닐)에틸]-4-피페리딘메탄올의용도 | |
| JP5165578B2 (ja) | イソキノリンおよびベンゾ［ｈ］イソキノリン誘導体、調製およびヒスタミンｈ３受容体のアンタゴニストとしてのこの治療上の使用 | |
| JP2010505919A5 (enExample) | ||
| CA3022188A1 (en) | Vinylogous phenethylamines as neurotransmitter releasers | |
| CN101247810A (zh) | 催眠药与R(+)-α-(2,3-二甲氧基-苯基)-1-[2-(4-氟苯基)乙基]-4-哌啶甲醇的组合及其治疗应用 | |
| EP2655326A1 (en) | 4- (hetero) aryl - ethynyl - octahydro - indole - 1 - carboxylic acid esters | |
| JP2017529379A5 (enExample) |